CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company’s Lead Compound CER-1236
Results in 17 Issued and Allowed Patent Applications Internationally with Nine Total Patent Families
SOUTH SAN FRANSCISCO, Calif, April 10, 2025 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces the allowance of two patent applications submitted to the U.S. Patent and Trademark Office (USPTO), which materially expands the Company’s intellectual property portfolio.
Patent Application No. 17/040,472, titled, “CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF,” was allowed on March 13, 2025 and provides coverage for composition of matter and methods of use coverage for the Company’s lead compound, CER-1236. The allowed claims encompass the combination of a phosphatidylserine-targeting CD4+ CER-T cell with a CD8+ CAR-T cell or a CD8+ recombinant TCR-T cell, and their use to treat cancer. This Notice of Allowance is expected to result in the issuance of a U.S. patent once administrative processes are completed.
Additionally, the USPTO has issued a Notice of Allowance on March 24, 2025 for Patent Application No. 17/040,317, titled, “CHIMERIC TIM4 RECEPTORS AND USES THEREOF.” The allowed claims encompass some design aspects of CER-1236. This patent, once granted, provides composition of matter protection for a chimeric TIM4 receptor comprising a TIM4 binding domain and canonical T cell signaling domains. CERo’s intellectual property portfolio now includes 9 total patent families with protection out to 2039 in the United States. With these additional allowed applications, CER-1236 and its platform technology is supported by 17 total issued patents and allowed patent applications internationally.
Chris Ehrlich, CERo Therapeutics CEO, commented, “These additional patent application allowances are paramount to CERo’s success in the market as they demonstrate the true novelty of our design and approach in potentially killing cancer cells and treating patients. The robust range of patents that cover this technology in general, and CER-1236 in particular, are a continuation of the validation we have seen since the inception of the Company, demonstrating innovation — and we believe – therapeutic potential. We are gratified to be receiving these allowances on the heels of the announcement of our initial trial site for our Phase 1 trial in AML and the announcement of our cleared IND to begin human trials to treat ovarian and non-small cell lung cancers.”
About CERo Therapeutics Holdings, Inc.
CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells (“CER-T”). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor (“CAR-T”) cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo anticipates initiating clinical trials for its lead product candidate, CER-1236, in 2025 for hematological malignancies.
Forward-Looking Statements
This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo and the implementation of its proposed plan of compliance with Nasdaq continued listing standards. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo’s management.
Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and the documents incorporated by reference therein. The risks described in CERo’s filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Chris Ehrlich
Chief Executive Officer
chris@cero.bio
Investors:
CORE IR
investors@cero.bio
